Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients with Ulcerative Colitis

Gastroenterology

Volumn 150, Issue 2, 2016, Pages 380-388.e4

  Carbonnel, Franck ^a,b   Colombel, Jean Frédéric ^c   Filippi, Jérome ^d   Katsanos, Konstantinos H ^e   Peyrin Biroulet, Laurent ^f   Allez, Mathieu ^g   Nachury, Maria ^b,h   Novacek, Gottfried ⁱ   Danese, Silvio ^j   Abitbol, Vered ^k   Bossa, Fabrizio ^l   Moreau, Jacques ^m   Bommelaer, Gilles ⁿ   Bourreille, Arnaud ^o   Fumery, Mathurin ^p   Roblin, Xavier ^q   Reinisch, Walter ^i,r   Bouhnik, Yoram ^s   Brixi, Hedia ^t   Seksik, Philippe ^u   Malamut, Georgia ^v   Färkkilä, Martti ^w   Coulibaly, Baya ^x   Dewit, Olivier ^y   Louis, Edouard ^z   Deplanque, Dominique ^aa   Michetti, Pierre ^ab   Sarter, Hélène ^aa   Laharie, David ^ac   Demolin, Julie ^ad   Détré, Patricia ^ad   Brillaut, Gaëlle ^ad   more..

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e UNIVERSITY OF IOANNINA   (Greece)

^f UNIVERSITÉ DE LORRAINE   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^k Institut Cochin   (France)

^l CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^m CHU RANGUEIL   (France)

ⁿ UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^o HÔTEL DIEU   (France)

^p AMIENS UNIVERSITY HOSPITAL   (France)

^q HÔPITAL NORD   (France)

^r MCMASTER UNIVERSITY   (Canada)

^s BEAUJON HOSPITAL   (France)

^t SERVICE DE DERMATOLOGIE   (France)

^u HÔPITAL SAINT ANTOINE   (France)

^v UNIVERSITÉ PARIS DESCARTES   (France)

^w UNIVERSITY OF HELSINKI   (Finland)

^x CENTRE HOSPITALIER D AVIGNON   (France)

^y UCL Saint Luc   (Belgium)

^z UNIVERSITY OF LIÈGE   (Belgium)

^aa UNIV LILLE   (France)

^ab LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^ac UNIVERSITÉ DE BORDEAUX   (France)

^ad NONE

more..

Author keywords

Clinical Trial; Drug; IBD; Methotrexate

Indexed keywords

METHOTREXATE; PLACEBO; PREDNISONE; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; GASTROINTESTINAL AGENT;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; ARTHRALGIA; ARTICLE; ASSESSMENT OF HUMANS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIARRHEA; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOSCOPY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEALING; HEALTH CARE FACILITY; HUMAN; INFLUENZA; INJECTION SITE REACTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MAYO SCORE; MULTICENTER STUDY; NAUSEA AND VOMITING; PAIN; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; COLITIS, ULCERATIVE; COLON; COMBINATION DRUG THERAPY; DRUG EFFECTS; EUROPE; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TIME FACTOR; WOUND HEALING;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; COLON; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MALE; METHOTREXATE; MIDDLE AGED; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; WOUND HEALING;

EID: 84959522321     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.10.050     Document Type: Article

References (28)

1. A. Timmer, J.W. McDonald, D.J. Tsoulis, and et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis Cochrane Database Syst Rev 9 2012 Sep 12 CD000478
2. M. Toruner, E.V. Loftus Jr., W.S. Harmsen, and et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease Gastroenterology 134 2008 929 936
3. L. Beaugerie, N. Brousse, A.M. Bouvier, and et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study Lancet 374 9701 2009 1617 1625
4. P. Rutgeerts, W.J. Sandborn, B.G. Feagan, and et al. Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2005 2462 2476
5. R. Panaccione, S. Ghosh, S. Middleton, and et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis Gastroenterology 146 2014 392 400
6. N. Nyboe Andersen, B. Pasternak, N. Friis-Møller, and et al. Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study BMJ 350 2015 Jun 5 h2809
7. B.G. Feagan, P. Rutgeerts, B.E. Sands, and et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis N Engl J Med 369 2013 699 710
8. M.E. van der Valk, M.J. Mangen, M. Leenders, and et al. COIN study group and the Dutch Initiative on Crohn and Colitis. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study Gut 63 2014 72 79
9. B.G. Feagan, J. Rochon, R.N. Fedorak, and et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators N Engl J Med 332 1995 292 299
10. B.G. Feagan, R.N. Fedorak, E.J. Irvine, and et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators N Engl J Med 342 2000 1627 1632
11. R. Oren, N. Arbert, S. Odes, and et al. Methotrexate in chronic active ulcerative colitis: a double blind randomized Israeli multicenter trial Gastroenterology 110 1996 1416 1421
12. N. Chande, Y. Wang, J.K. MacDonald, and et al. Methotrexate for induction of remission in ulcerative colitis Cochrane Database Syst Rev 8 2014 CD006618
13. E.F. Stange, S.P. Travis, S. Vermeire, and et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis J Crohns Colitis 2 2008 1 23
14. P.J. Brooks, W.J. Spruill, R.C. Parish, and et al. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis Arthritis Rheum 33 1990 91 94
15. J.W. Jundt, B.A. Browne, G.P. Fiocco, and et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing J Rheumatol 20 1993 1845 1849
16. H.H. Herfarth, M.T. Osterman, K.L. Isaacs, and et al. Efficacy of methotrexate in ulcerative colitis: failure or promise Inflamm Bowel Dis 16 2010 1421 1430
17. S. Ardizzone, G. Maconi, A. Russo, and et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis Gut 55 2006 47 53
18. A. Wilson, V. Patel, N. Chande, and et al. Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease Aliment Pharmacol Ther 37 2013 340 345
19. M.H. Schiff, J.S. Jaffe, and B. Freundlich Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration Ann Rheum Dis 73 2014 1549 1551
20. B.G. Feagan, W.J. Sandborn, G. D'Haens, and et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis Gastroenterology 145 2013 149 157
21. B. Jharap, W.J. Sandborn, W. Reinisch, and et al. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis Aliment Pharmacol Ther 42 2015 1082 1092
22. X. Mariette, D. Cazals-Hatem, J. Warszawki, and et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France Blood 99 2002 3909 3915
23. N. Nyboe Andersen, B. Pasternak, S. Basit, and et al. Association between tumor necrosis factor α antagonists and risk of cancer in patients with inflammatory bowel disease JAMA 311 2014 2406 2413
24. M.T. Osterman, W.J. Sandborn, J.-F. Colombel, and et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease Gastroenterology 146 2014 941 949
25. L. Peyrin-Biroulet, K. Khosrotehrani, F. Carrat, and et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease Gastroenterology 14 2011 1621 1628
26. J. Maté-Jiménez, C. Hermida, J. Cantero-Perona, and et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease Eur J Gastroenterol Hepatol 12 2000 1227 1233
27. W.J. Sandborn, G. van Assche, W. Reinisch, and et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 142 2012 257 265
28. W.J. Sandborn, B.G. Feagan, C. Marano, and et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis Gastroenterology 146 2014 96 109